Workflow
Quantum BioPharma Corporate Update
QMCOQuantum(QMCO) Newsfile·2025-04-19 00:00

Corporate Updates - Quantum BioPharma Ltd. announced the grant of 60,000 restricted share units (RSUs) under its equity incentive plan, which are subject to vesting criteria and a hold period of four months and one day [2] - The board of directors approved the settlement of outstanding debt by issuing Class B Shares at a deemed price of US6.75pershare,alsosubjecttoafour−monthandone−dayholdperiod[3]CompanyOverview−QuantumBioPharmaisfocusedondevelopinginnovativebiopharmaceuticalsolutionsforneurodegenerativeandmetabolicdisorders,aswellasalcoholmisusedisorders,withdrugcandidatesatvariousdevelopmentstages[1][4]−Thecompany’sleadcompound,Lucid−MS,isapatentednewchemicalentityaimedatpreventingandreversingmyelindegradation,akeyfactorinmultiplesclerosis,demonstratedinpreclinicalmodels[4]−QuantumBioPharmaretainsa25.716.75 per share, also subject to a four-month and one-day hold period [3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates at various development stages [1][4] - The company’s lead compound, Lucid-MS, is a patented new chemical entity aimed at preventing and reversing myelin degradation, a key factor in multiple sclerosis, demonstrated in preclinical models [4] - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product UNBUZZD™, and is entitled to 7% royalty payments on sales until reaching 250 million, after which the royalty rate will drop to 3% indefinitely [4]